• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

New Strategy for High Throughput Screening of Anti- Influenza virus M2 Ion Channel Inhibitors

tetano

Editor, Senior Moderator
Curr Pharm Des. 2013 Apr 26. [Epub ahead of print]
New Strategy for High Throughput Screening of Anti- Influenza virus M2 Ion Channel Inhibitors.
Li C, Long Y, Lin Z, Jie Y, Xiao Y, Yang L, Sun J, Ren Y, Chen L, Li Z.
Source

State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences (GIBH), #190 Kai-Yuan Road, Guangzhou Science Park, Guangzhou 510530, China. li_zhiyuan@gibh.ac.cn; chen_ling@gibh.ac.cn.
Abstract

Since the recent emergence of swine and avian flu, there has been a sense of urgency to discover new anti-influenza drugs. In this study, a stable cell line with M2 ion channel/ enhanced Green fluorescent protein (EGFP) co-expression was established in order to develop an EGFP-based high-throughput assay for screening M2 ion channel inhibitors. This assay directly monitors the proton conductivity of the M2 ion channel by measuring the fluorescence intensity of EGFP, which is dependent on and sensitive to pH. The ability of amantadine to inhibit the M2 ion channel was detected by this novel EGFP-based assay and then confirmed by a patch clamp recording assay. With this assay, (1S,2S,3S,5R)-(+)-3-Isopinocampheylamine and (1R,2R,3R,5S)-(-)-3-Isopinocampheylamine were identified to inhibit M2 ion channel with an antiviral profile similar to that of amantadine. This new technique will facilitate the discovery of pharmaceutical candidates and will aid in the development of new, potent, and safe anti-influenza agents.

PMID:
23621591
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23621591
 
Back
Top Bottom